ArticleAACE endocrinology and diabetes
Novel Homozygous MTHFR Variant Causing Homocystinuria: Subtle Phenotypic Clues in Carriers.
Article in AACE endocrinology and diabetes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Homocystinuria is a rare metabolic disorder characterized by elevated homocysteine levels due to defects in methionine metabolism. Case Report: We present a 17-year-old male with tall stature, intellectual disability, and skeletal abnormalities. Elevated plasma homocysteine levels 199.95 μmol/L were noted, which increased to 225.04 μmol/L following pyridoxine therapy, indicating nonresponsiveness. Genetic analysis revealed a novel homozygous missense variant in exon 12 of the MTHFR gene (p.Lys625Thr). Notably, the carrier father exhibited an increased arm span-to-height ratio and raised serum homocysteine level 25.78 μmol/L, a subtle phenotypic and biochemical trait absent in the carrier mother. Management included a low-methionine diet, vitamin supplementation, and initiation of betaine therapy. Discussion: This case underscores the importance of genetic testing and individualized management in homocystinuria, especially with novel mutations. The observed subtle phenotypic feature in the carrier father highlights the need for comprehensive family evaluations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.